Corlanor (Ivabradine) Dosing
Start ivabradine at 5 mg twice daily with food in adults with heart failure, assess after 2 weeks, and titrate by 2.5 mg increments to achieve a resting heart rate of 50-60 bpm, with a maximum dose of 7.5 mg twice daily. 1
Initial Dosing
Standard starting dose: 5 mg twice daily with food 1
Lower starting dose (2.5 mg twice daily): Use this reduced dose in patients with:
- History of conduction defects
- Risk of hemodynamic compromise from bradycardia
- Elderly patients
- Renal impairment 1
Titration Schedule
Assess the patient after 2 weeks and adjust based on resting heart rate 1:
| Resting Heart Rate | Action |
|---|---|
| >60 bpm | Increase by 2.5 mg twice daily (max 7.5 mg twice daily) |
| 50-60 bpm | Maintain current dose |
| <50 bpm or symptomatic bradycardia | Decrease by 2.5 mg twice daily; discontinue if already on 2.5 mg twice daily |
Patient Selection Criteria
Ivabradine should only be used in patients meeting all of the following 2, 3:
- LVEF ≤35%
- Sinus rhythm (not atrial fibrillation)
- Resting heart rate ≥70 bpm (benefit greatest at ≥75 bpm 4)
- NYHA Class II-III symptoms
- On maximally tolerated beta-blocker or contraindication to beta-blockers
- Stable on guideline-directed medical therapy for ≥4 weeks
Critical Timing Consideration
Optimize beta-blockers first. Only 25% of patients in the pivotal SHIFT trial were on optimal beta-blocker doses 3. Given beta-blockers' proven mortality benefit, uptitrate them to target doses before adding ivabradine. The mortality benefit of beta-blockers is superior to ivabradine's primary benefit of reducing heart failure hospitalizations 5.
Renal Impairment
The FDA label does not specify dose adjustments for moderate renal impairment 1. However, start at 2.5 mg twice daily in patients with renal dysfunction as a precautionary measure, given the increased risk of bradycardia and hemodynamic compromise 1.
Expected Benefits and Timeline
- Primary benefit: Reduction in heart failure hospitalizations (26% relative risk reduction) 5
- Time to benefit: Significant reduction in the primary outcome occurs at 102 days in patients with HR ≥70 bpm, but only 67 days in those with HR ≥75 bpm 4
- Heart failure death reduction: 26% relative risk reduction 5
- The benefit is driven predominantly by reduced hospitalizations rather than cardiovascular mortality 3, 5
Common Pitfalls
Symptomatic bradycardia occurs in 5% of patients 5. Monitor heart rate closely during titration. If bradycardia develops, reduce to the previous dose step immediately 1.
Visual side effects (phosphenes) occur in 3% of patients—transient brightness in visual field, typically triggered by sudden light changes 5. These are generally benign but should be discussed with patients upfront.
Avoid concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, grapefruit juice) as these significantly increase ivabradine levels and bradycardia risk.